Drugs / SHR7280
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06969664 | May → Jul 2025 | endometriosis, leiomyoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06949124 | Apr → Jun 2025 | endometriosis, uterine benign neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06408948 | Jun → Jul 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05868057 | May → Jun 2023 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04995042 | Sep 2021 → May 2023 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04554043 | Sep 2020 → Sep 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04417972 | Jul 2020 → May 2024 | endometriosis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05082233 | Mar 2022 → Aug 2023 | female infertility due to oocyte meiotic arrest | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05442827 | Sep 2022 → Jun 2026 | uterine corpus leiomyoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05994378 | Aug 2023 → May 2025 | female infertility | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR7280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06969664 ↗ |
| Action | Inhibit | “SHR7280, an oral non-peptide GnRH antagonist” PMID 37838623 ↗ Oct 2023 |
| Modality | Small molecule | “SHR7280, an oral non-peptide GnRH antagonist” PMID 37838623 ↗ Oct 2023 |
| Route | Oral | “SHR7280, an oral non-peptide GnRH antagonist” PMID 37838623 ↗ Oct 2023 |